Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Vir Biotechnology has a strong cash position and is poised to generate definitive data in antivirals and oncology, making ...

An interim consultation response outlining regulators’ aims to include energy-from-waste operations in the Emissions Trading Scheme (ETS) as a mandatory ...

Pharmacies in Canada are experiencing a digital shift. With virtual consults, online prescription renewals, and cloud-based ...

Track Change to Navigate Disruption and Regain Balance CHICAGO, July 23, 2025 /PRNewswire/ -- Healthcare systems make swift changes to ...

Analysts have recently evaluated IQVIA Hldgs and provided 12-month price targets. The average target is $177.67, accompanied by a high estimate of $196.00 and a low estimate of $160.00. Experiencing a ...

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychother ...

Q2 2025 Earnings Call Transcript July 22, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $2.81, expectations were $2.77. Operator: Ladies and gentlemen, thank you for standing ...

As Europe’s healthcare systems grapple with aging populations, rising chronic disease, and overburdened clinicians, digital ...

Purple Biotech Ltd. ('Purple Biotech' or 'the Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

At the HIMSS APAC 2025 conference, GuidelineX made a powerful impact with its next-generation, AI-native Clinical Decision ...